PetVivo Holdings, Inc. (PETV) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates mixed signals: improved balance sheet and strategic cost reductions are positive, but increased operating loss and lack of clear guidance are concerning. The Q&A reveals management's uncertainty about guidance and revenue expectations, which could worry investors. While there are promising developments in product launches and market expansion, the absence of NASDAQ listing plans and unclear future projections temper enthusiasm, leading to a neutral sentiment.
Key Financial Performance
Revenues for the 9 months ended December 31, 2025 $887,000, decreasing only 2% from the same year ago period. The slight decrease was primarily due to a decrease in Spryng product sales, offset by an increase in sales of PrecisePRP. The decrease in Spryng sales was attributed to the absence of a special promotion held in the prior year and customers opting to use PrecisePRP alone.
Gross profit for the first 9 months $551,500 or 62.2% of revenues, which decreased from $812,000 or 89% of revenues in the same period a year ago. The decrease was due to the lower gross margins of the PrecisePRP product line and a greater proportion of this lower-margin product in the sales mix.
Total operating expenses $6.7 million, decreased 2% compared to the same year-ago period. The improvement was due to reduced general and administrative costs and research and development costs, reflecting a strategic cost reduction and restructuring program.
Operating loss $6.1 million, increased 2% from $6 million in the same year-ago period. The increase was primarily due to increased sales and marketing expenses related to the rollout of the new PrecisePRP product line.
Net loss for the first 9 months $7.5 million or $0.27 per share, compared to a net loss of $6 million or $0.30 per share for the same year-ago period. The increase was due to unrealized loss on change in derivative liabilities, loss on disposal of certain assets, amortization of debt discount, and interest expense on convertible notes.
Net cash used in operating activities during the 9 months $5.3 million, primarily attributed to a decrease in accounts payables and accrued expenses of $840,000 and the increase in PrecisePRP production and inventory purchases to meet market demand.
Current assets as of December 31, 2025 $1.4 million, while current liabilities were significantly reduced to $980,000 from $4.2 million in the same period last year. This reflects a substantial improvement in the balance sheet.
Total liabilities as of December 31, 2025 $1 million, down from $5.1 million on March 31, 2025, representing an 81% decrease. This was due to the conversion of all convertible notes into common stock, extinguishment of derivative liabilities, and reduction in accounts payables and accrued expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of PetVivo AI: PetVivo AI is a new AI-powered Software-as-a-Service platform for veterinarians, powered by AgenticPet AI technology. It reduces veterinary customer acquisition costs by 50%-90% and creates a new recurring revenue stream with high gross margins.
PrecisePRP Commercialization: PrecisePRP, a platelet-rich plasma product for horses and dogs, complements the Spryng product line and has been well-received by veterinarians.
Functional Biomaterials Development: Partnership with PiezoBioMembrane to develop advanced biomaterials for tissue and bone regeneration, with commercialization expected by late 2026 or early 2027.
Expansion into Canada: Health Canada recognized Spryng as a veterinary medical device, opening the Canadian market with a projected growth to $4.4 billion by 2031.
European Market Entry: Engagement with Nupsala Group to distribute Spryng in the U.K., with training and inventory already underway.
Mexico Market Expansion: Signed Eq Especialidades for distribution in Mexico, a market projected to grow at 11% CAGR to $2.4 billion.
Strategic Alliances: Partnerships with Digital Landia for AI technology and Veterinary Growth Partners to promote products to over 7,300 U.S. veterinary clinics.
Financial Improvements: Significant reduction in liabilities by 81% and improved working capital to $395,000.
Focus on AI and Regenerative Medicine: Strategic shift towards AI-driven solutions and regenerative medicine to address veterinary challenges and expand market presence.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Adoption Challenges: The company faces challenges in achieving broad market adoption of its flagship product, Spryng, and new products like PetVivo AI. Despite positive feedback, the adoption rates and market penetration remain uncertain.
Revenue Decline: Revenues for the 9 months ended December 31, 2025, decreased by 2% compared to the same period last year, primarily due to a decline in Spryng product sales.
Product Mix and Margins: The shift in product mix, with increased sales of lower-margin PrecisePRP products, has negatively impacted gross margins. Efforts to improve margins and educate customers on using both Spryng and PrecisePRP together are ongoing but not guaranteed to succeed.
Regulatory and R&D Risks: The company is heavily reliant on the successful completion of R&D stages and regulatory approvals for new products, including functional biomaterials and FDA clearance for human applications. Delays or failures in these areas could impact commercialization timelines.
Financial Sustainability: The company reported a net loss of $7.5 million for the first 9 months of fiscal 2026, with significant cash used in operating activities. While liabilities have decreased, financial sustainability remains a concern.
Competitive Pressures: The company operates in a highly competitive market, particularly with the launch of its AI-powered solutions. Maintaining a first-mover advantage and differentiating its offerings will be critical.
Supply Chain and Production Risks: The ability to mass-produce new products like functional biomaterials at scale has been demonstrated, but any disruptions in the supply chain or production processes could delay commercialization.
International Market Risks: While expanding into international markets like Canada, Mexico, and Europe, the company faces risks related to regulatory compliance, market acceptance, and operational challenges in these regions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Launch of PetVivo AI: The company plans to publicly launch its new PetVivo AI veterinary practice platform, powered by AgenticPet AI technology, which is expected to reduce veterinary customer acquisition costs by 50%-90% and create a new recurring revenue stream with high gross margins (80%-90%).
Expansion of Product Portfolio: The company anticipates launching new functional biomaterials for animals and humans by late 2026 or early 2027, following the completion of Stage C of R&D and FDA clearance for human applications.
Commercialization of PrecisePRP: The company is advancing the commercial launch of PrecisePRP, a regenerative product for horses and dogs, and plans to drive greater adoption through industry conferences and collaborations.
International Market Expansion: The company is preparing for the official launch of Spryng in Canada by Q3 2026, following Health Canada's recognition of the product. It is also expanding into the European and Mexican markets, with significant growth potential in these regions.
Market Growth Projections: The U.S. animal health market is expected to double to $11.3 billion by 2030, providing strong growth opportunities for the company.
Strategic Partnerships: The company is collaborating with Veterinary Growth Partners to promote its products to over 7,300 veterinary clinics in the U.S. and with Nupsala Group to distribute products in the U.K.
R&D Advancements: The company is conducting additional studies on Spryng and PrecisePRP and developing new biomaterials to enhance tissue and bone regeneration in animals and humans.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the update on getting listed on NASDAQ?
A:The plan is not for NASDAQ but for New York Amex. The company is working towards that, and it depends on stock price and the life science microcap market. They anticipate achieving the necessary pricing as future events occur.
Q:Can you provide an update on the previous guidance given in the last conference call in light of this quarter's results?
A:John Lai deferred to Garry Lowenthal, who stated he did not recall the guidance. The analyst mentioned it was $2 million to $2.5 million for the fiscal year. Garry explained that revenues were down due to changes in product ordering patterns and new product launches. He also mentioned acquisitions and a new product pipeline that will monetize later in the year.
Q:Are you pushing out the uptick in sales, and should we expect the previous guidance to be reflected in the next conference call?
A:Garry Lowenthal explained that the company changed its sales model, which impacted revenue distribution. They are enhancing their sales organization and outsourcing to a third-party organization for inside sales. He did not confirm if the previous guidance would be reflected in the next call.
Q:What CapEx is required to roll out the education of the veterinarian system on the Digital Landia platform, and who is responsible for the rollout?
A:John Lai explained that the rollout involves multiple aspects, including onboarding clinics and using an open architecture platform. Digital Landia is responsible for providing updates and the functional system. PetVivo's CapEx is minimal, mainly involving promotional efforts.
Q:Will PetVivo recognize revenues from the implementation of the system by vets?
A:Yes, PetVivo will recognize revenues as vets save costs and adopt the SaaS model. The system is expected to enhance the ecosystem for vets and clinic ownership.
Q:Who will support the ecosystem for the PetVivo.ai system?
A:Digital Landia is responsible for supporting the ecosystem, including updates and functionality. PetVivo's expenditure will focus on promoting the system to veterinary clinic groups.
Q:Do you have expectations for revenues and P&L for the next year or two?
A:John Lai stated they are not providing guidance on the pet side yet. Garry Lowenthal added that the revenue model is recurring and involves a freemium-to-premium transition.
Q:Is Digital Landia or PetVivo's AI system a direct-to-consumer marketing platform?
A:John Lai clarified that it is primarily focused on veterinary doctors but also has a dual ecosystem that includes direct-to-consumer marketing. The system allows vets to identify potential customers and offer promotions.
Q:What adoption rate is expected for the Digital Landia's PetVivo.ai platform?
A:John Lai mentioned that subscription model platforms generally have a 20-25% conversion rate from trial to paying customers. The platform is based on a SaaS model with AI-driven efficiencies.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the question about revenue and P&L expectations for the next year or two, stating they are not providing guidance yet. Additionally, there was some lack of clarity regarding the previous guidance mentioned by the analyst, as both John Lai and Garry Lowenthal did not recall the specific guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI agent
AI practice
AI solution
AgenticPet AI
American Association
BB
Digital Landia
Florida
Health Canada
Landia launch
PetVivo AI
Practitioners Conference
PrecisePRP product
RD
Stage
VGP
beta
capital
customer
engagement
healthcare
human
liability
margin
market opportunity
mix
month period
note
offering
paper
parent
platform
product line
product sale
result month
vendor
PETV Transcript
PetVivo Holdings, Inc. (PETV) Q3 2026 Earnings Call Transcript
Unknown2-17
The earnings call summary indicates mixed signals: improved balance sheet and strategic cost reductions are positive, but increased operating loss and lack of clear guidance are concerning. The Q&A reveals management's uncertainty about guidance and revenue expectations, which could worry investors. While there are promising developments in product launches and market expansion, the absence of NASDAQ listing plans and unclear future projections temper enthusiasm, leading to a neutral sentiment.
PetVivo Holdings, Inc. (PETV) Q2 2026 Earnings Call Transcript
Positive11-14
The earnings call revealed strong revenue growth and market expansion potential, particularly in the animal health sector. Despite a decrease in gross margins and an increased net loss, the company's strategic initiatives, including partnerships and product launches, are promising. The Q&A highlighted management's transparency about revenue sources and adoption challenges, though specifics were lacking. The strategic partnerships and record revenue growth are positive indicators. Given these factors, the stock price is likely to see a positive movement over the next two weeks.
PetVivo Holdings, Inc. (PETV) Q1 2026 Earnings Call Transcript
Unknown8-14
The earnings call summary shows mixed signals: strong revenue growth and new partnerships are positive, but high operating losses, cash flow concerns, and reliance on distributors are negative. The Q&A didn't reveal new insights or strong analyst sentiment. Despite record revenue growth, margin pressure and financial health concerns weigh heavily, balancing out the positives. Without clear guidance or market cap data, the overall sentiment is neutral, suggesting a stock price movement within the -2% to 2% range.
PetVivo Holdings, Inc. (PETV) Q4 2025 Earnings Call Transcript
Unknown6-30
The earnings call highlights financial challenges, including a net loss and cash constraints, despite revenue growth. Regulatory compliance issues and potential dilution from Series B conversion add to investor concerns. The Q&A reveals management's evasive responses and competitive pressures. While there is optimism about human trials, the overall sentiment is negative due to financial sustainability issues and market penetration challenges.
PETV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
